CSS LLC’s Sarepta Therapeutics SRPT Stock Holding History

CSS LLC’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-6,700	Closed	-$767K	–	931
2023 Q2	$767K	Buy	+6,700	New	+$864K	0.05%	292
2022 Q4	–	Sell	-1,601	Closed	-$186K	–	1089
2022 Q3	$177K	Buy	+1,601	New	+$161K	0.01%	765
2021 Q2	–	Sell	-3,076	Closed	-$229K	–	1169
2021 Q1	$229K	Buy	3,076 +1,708	+125%	+$158K	0.01%	738
2020 Q4	$233K	Buy	+1,368	New	+$203K	0.01%	608
2020 Q2	–	Sell	-598	Closed	-$81.4K	–	755
2020 Q1	$58K	Buy	+598	New	+$68.4K	﹤0.01%	527

Other funds holding SRPT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

CSS LLC's SRPT Position: Q3 2023 in Review

CSS LLC sold out of Sarepta Therapeutics (SRPT) in Q3 2023, closing a stake of 6,700 shares — an estimated $767K sold.

CSS LLC first reported a position in SRPT in Q1 2020 and held it in 5 quarters. The position peaked at $767K in Q2 2023. 394 funds tracked by Wall St. Rank hold SRPT as of Q3 2023.

CSS LLC reported no remaining Sarepta Therapeutics position as of Q3 2023 after selling out during the quarter.
CSS LLC sold 6,700 Sarepta Therapeutics shares in Q3 2023, an estimated $767K.
CSS LLC first reported a position in Sarepta Therapeutics in Q1 2020 and held it in 5 quarters.
CSS LLC's Sarepta Therapeutics position peaked at $767K in Q2 2023.
394 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q3 2023.

Based on CSS LLC's 13F filing for Q3 2023, filed 14 Nov 2023.